Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321873 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
A Phase 2 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 19
- Study locations
NCT07321873: Recruiting Phase 2 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.
NCT07321873 is a Phase 2 study of Arthritis, Psoriatic that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 240 participants, below the 561-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (57% lower). The trial reports 19 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07321873, a Phase 2 study of Arthritis, Psoriatic, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joint and skin health.
Primary Outcome
The ACR 50 responders are participants with an improvement of greater than or equal to (\>=) 50 percent (%) from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain visual analog scale \[VAS\], patient's global assessment of disease activity \[arthritis, VAS\] scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-88545223
Study Locations (19)
Other
- Peking University People's Hospital - Beijing
- Ningbo medical center lihuili hospital - Ningbo
- Hospital of the University of Occupational and Environmental Health - Kitakyushu-shi
- Osaka Metropolitan University Hospital - Osaka
- Sanuki Municipal Hospital - Sanuki
Florida
- American Research, LLC - Cutler Bay
- Innovation Medical Research Center - Palmetto Bay
- Clinical Research of West Florida - Tampa
- Conquest Research - Winter Park
California
- Newport Huntington Medical Group - Huntington Beach
- Rheumatology Center of San Diego - San Diego
Arkansas
- Unity Health-White County Medical Center - Searcy
Georgia
- Atlanta Research Center for Rheumatology - Marietta
Illinois
- Willow Rheumatology and Wellness PLLC - Willowbrook
Indiana
- Qualmedica Research - Evansville
North Carolina
- Joint and Muscle Research Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-08-02 |
| Phase | Phase 2 |
What NCT07321873 shows while recruiting
NCT07321873 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 561-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07321873 lists 19 locations in 11 states (Other, Florida, California).
Frequently Asked Questions
What is clinical trial NCT07321873 about?
NCT07321873 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis". The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joi...
What is the current status of trial NCT07321873?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-01-15. Estimated completion is 2027-08-02.
What conditions does trial NCT07321873 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT07321873?
The interventions under investigation include: Placebo (DRUG), JNJ-88545223 (DRUG).
Who is sponsoring clinical trial NCT07321873?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07321873 being conducted?
This trial has 19 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07321873's enrollment target sits among peer trials
240 11th of 16 higher than 6 of 16 other Arthritis, Psoriatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Psoriatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
COMPLETED · Phase 2
-
Low Dose Naltrexone for Chronic Pain From Arthritis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI